Previous close | 225.31 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | 2.228B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 0.38 |
EPS (TTM) | 6.52 |
Earnings date | 08 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$373 Current share price of...
UK chancellor Jeremy Hunt has told drugmakers that the government has no “magic wand” to deal with financial pressures and was unlikely to give into industry demands to pay a significantly higher price for medicines. The government will on Friday unveil reforms worth £650mn to boost the life sciences sector as part of a wider package of measures. Drugmakers have condemned the government for this year increasing a tax on sales of drugs to the NHS to 26.5 per cent, from 5.1 per cent over the past two years.
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's ambitious sustainability goals, which are critical to maintaining a strong and resilient company.
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
The New England Journal of Medicine today published detailed results from Eli Lilly and Company's (NYSE: LLY) phase 2a study of peresolimab in rheumatoid arthritis (RA), in which peresolimab met the primary endpoint for efficacy and had similar rates of adverse events between peresolimab and placebo arms. These data represent the first clinical evidence that stimulating the endogenous PD-1 inhibitory pathway could be an effective approach to treat rheumatologic disease. The phase 2a clinical tri
(Bloomberg) -- European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching.Most Read from BloombergHere’s How Much Wealth You Need to Join the Richest 1% GloballyMercedes Sets Out to Make Sexy Vans With Yacht-Like InteriorsJPMorgan Asset Says Markets Are Right to Bet on US Rate CutsDebt-Limit Talks to Intensify as Biden Set to Depart for JapanSeveral major drugmakers keen to expand in immunology have been studying the $23 bi
Key Insights Significantly high institutional ownership implies Eli Lilly's stock price is sensitive to their trading...
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat. Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.
The stock market's short-term volatility can sometimes cloud investors' judgment and cause panic selling. In that spirit, we asked three Motley Fool contributors to discuss buy-and-hold-worthy growth stocks. Read on to find out why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).
Most investors are comfortable with the idea of businesses like Apple and Microsoft having market caps in excess of $1 trillion. Today, Eli Lilly's market cap is a little north of $410 billion, which puts it among the top handful of big pharma companies. Its trailing 12-month net income is $6.2 billion, and its trailing price-to-earnings ratio is near 69, which is fairly high, but not at bloated tech stock levels.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Few pharmaceutical giants have performed as well or better than Eli Lilly (NYSE: LLY) in the stock market over the past year. The Indianapolis-based company's secret wasn't its financial results, as they were relatively mild, or even downright disappointing, for much of this period. The market is forward-looking, and with the drugmaker producing several highly promising programs, investors are increasingly excited regarding Eli Lilly's future.
Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.
Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the 2023 European Hematology Association (EHA) Annual Meeting, to be held June 8 – 11, 2023, in Frankfurt, Germany, and virtually. The company-sponsored abstracts include new analyses of clinical data in approved and investigational uses based on the BRUIN Phase 1/2 trial evaluating Jaypirca™ (pirtobrutinib) in patients with B-cell malignancies previously
The headline inflation figure rose at the slowest rate in more than two years.
Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.
Eli Lilly, Verizon Communications, United Parcel Service, Advanced Micro Devices and The Cigna Group are part of the Zacks Analyst Blog.
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting the company's commitment to going beyond the medicines it makes to have a positive impact on patients and society through for-profit investments.
Eli Lilly and Company (NYSE: LLY) announced today new investigational data for mirikizumab in patients with moderately to severely active ulcerative colitis (UC) that further support the efficacy and safety seen in previous pivotal studies.
Shares of Eli Lilly (NYSE: LLY) climbed 15.3% last month, according to S&P Global Market Intelligence. Promising drug trial developments and a strong outlook from management in its first-quarter report provided the upward momentum to the pharmaceutical stock. Eli Lilly caught Wall Street's attention early in April after announcing positive results from an early clinical trial for an experimental Alzheimer's drug.